| Target Price | $8.16 |
| Price | $3.96 |
| Potential |
106.06%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Adc Therapeutics SA 2026 .
The average Adc Therapeutics SA target price is $8.16.
This is
106.06%
register free of charge
$10.50
165.15%
register free of charge
$5.05
27.53%
register free of charge
|
|
| A rating was issued by 12 analysts: 11 Analysts recommend Adc Therapeutics SA to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adc Therapeutics SA stock has an average upside potential 2026 of
106.06%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 70.84 | 79.19 |
| 1.84% | 11.78% | |
| EBITDA Margin | -182.55% | -213.83% |
| 22.95% | 17.13% | |
| Net Margin | -222.83% | -220.99% |
| 35.43% | 0.82% |
8 Analysts have issued a sales forecast Adc Therapeutics SA 2025 . The average Adc Therapeutics SA sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Adc Therapeutics SA EBITDA forecast 2025. The average Adc Therapeutics SA EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Adc Therapeutics SA Analysts have issued a net profit forecast 2025. The average Adc Therapeutics SA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.62 | -1.56 |
| 44.90% | 3.70% | |
| P/E | negative | |
| EV/Sales | 8.51 |
8 Analysts have issued a Adc Therapeutics SA forecast for earnings per share. The average Adc Therapeutics SA EPS is
This results in the following potential growth metrics and future valuations:
Adc Therapeutics SA...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jun 20 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jun 13 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 13 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 20 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jun 13 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


